By Cecilia Butini

 

Novartis AG said Monday that a trial evaluating breast-cancer drug Kisqali met its primary endpoint during an interim analysis.

The drug is shown to significantly reduce the risk of disease recurrence when used together with an endocrine therapy in patients with certain types of early breast cancers at risk of recurrence, the company said.

The Phase 3 trial, named Natalee, was stopped early as the primary endpoint has been met, Novartis said.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

March 27, 2023 01:41 ET (05:41 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Novartis Charts.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Novartis Charts.